Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

tion toxicities were generally similar between the radiation therapy alone and the ERBITUX plus radiation therapy arms.

The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).

About ImClone Systems

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:3/3/2015)... Actavis plc (NYSE: ACT ) today announced ... aggregate principal amount of senior unsecured notes in 10 ... by its indirect wholly-owned subsidiary, Actavis Funding SCS, and ... as follows: Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... , Due 2016 , 100.00% 1.850% Senior ...
(Date:3/3/2015)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... present at the 27 th Annual ROTH Conference, which ... Point, California from March 8 to March 11. ... Palmieri , will be presenting on Monday, March 9 at ... Schoen , the company,s Vice President of Finance and Chief ...
(Date:3/3/2015)... Fla. , March 3, 2015 ... pleased to announce the hiring of Brian ... to lead business development efforts and build relationships ... of experience in software development, sales, and sales ... enterprise software applications. iTraycer is a comprehensive inventory ...
Breaking Medicine Technology:Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10Vermillion To Present at 27th Annual ROTH Conference on March 9 2Medical Tracking Solutions, Inc. Hires New SVP, Sales 2
... LAWRENCE, Mass., Jan. 4, 2011 NxStage Medical, Inc. ... innovative dialysis products, today announced that Jeffrey H. Burbank, ... Officer, will present at the 29th Annual J.P. Morgan ... a.m. (PST). The live webcast of NxStage,s ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... granted orphan drug designation from the U.S. Food and ... Clostridium difficile infection (CDI).  This orphan drug designation ... of fidaxomicin used to treat Clostridium difficile ...
Cached Medicine Technology:NxStage to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 3Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 4
(Date:3/3/2015)... 2015 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced that ... SaaS Workforce Management / Time and Attendance ... , Since 2004, Innovative Services’ mission has ... the best quality of life. The company is ...
(Date:3/3/2015)... New York, New York (PRWEB) March 03, 2015 ... that question tactics used to market the atypical ... around the U.S. According to court documents, the ... jury’s 2011 finding that Johnson & Johnson’s Janssen ... concealed its serious risks. However, while the Court’s ...
(Date:3/3/2015)... On February 21st, the rooftop of the ... a day-long event that features a gathering of providers ... Organized by Debbie Durkin and Durkin Entertainment, Los Angeles’ ... EcoLuxe Lounge saw many notable attendees. Among them was ... The Flash, Star Trek: Deep Space Nine and many, ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Loma Linda ... whole health and well being, it will be offering ... across its campuses. , Over the past year, a ... part in creating dietary criteria, listening to vendors, sampling ... the entire organization. , Most recently, a food ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Longtime parent ... with CARE Surrogacy Center for a candid ... originally appearing online is an exhilarating revelation of his ... have led him from Australia to the birth of ... press interchange, Tolga Umar, CEO and Founder of CARE ...
Breaking Medicine News(10 mins):Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 3
... Cell-Based ... Melanoma Therapy, BOTHELL, Wash., ... developer and marketer of,proprietary hypothermic storage and cryopreservation media products for,cells, ... products in the cellular therapy and cord blood banking,market segments., ...
... Michelle Reesman, RN, Executive,Director, Passport Health Colorado, says far ... adventurous types, leave,home without taking the basic steps she ... preparation into their health as they do into their,destination ... 1) Get advice from a travel health ...
... LENEXA, Kan., Mar. 26 Mediware Information,Systems (Nasdaq: ... systems for,blood and medication management, has announced its ... hospital,blood banks and LifeTrak(R) software for blood centers, ... standards being required in the,United States., With ...
... for Voters on Health Care and,Social Security, ... said the most recent Medicare trustees, report calls ... issues.,According to the program,s trustees, Medicare,s Hospital Insurance ... Medicare must,rely also on interest accrued on trust ...
... 26 Spheris, a leading global,outsource provider of clinical ... and twelve months ended December 31, 2007., Financial ... fourth quarter of 2007 were $48.6 million compared,with $51.4 ... million decrease,in net revenues during the fourth quarter of ...
... a company,developing breakthrough molecular imaging agents for ... it has entered into a licensing,agreement with ... and,commercialization of agents for diagnosis and treatment ... were co-developed by,FluoroPharma and MGH scientists, target ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: